By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Daiichi Sankyo Company, Ltd. 

3-5-1, Nihonbashi-honcho

Chuo-ku  Tokyo  103-8426  Japan
Phone: +81-3-6225-1111 Fax:


Daiichi Sankyo is focused on the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class treatments that address unmet medical needs. The oncology pipeline of Daiichi Sankyo continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers.




CEO: Joji Nakayama


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Private

Web Site: Daiichi Sankyo


Company News
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017 8:42:50 AM
Daiichi Sankyo to Shutter Indian R&D Center, 170 Employees Affected 1/11/2017 6:12:41 AM
On a Roll: Kite Pharma (KITE) Bags $250 Million CAR-T Deal From Daiichi Sankyo, Forms Joint Venture With Fosun Pharma 1/9/2017 2:30:05 PM
Daiichi Sankyo And DarwinHealth Announce Strategic Partnership To Deploy A Quantitative Systems Biology Discovery Platform To Prioritize Daiichi Sankyo Cancer Enterprise Compounds For Development 12/13/2016 6:32:47 AM
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology 12/5/2016 9:50:53 AM
Daiichi Sankyo Announces New Subgroup Analyses Of Once-Daily SAVAYSA (Edoxaban) In Patients With Non-Valvular Atrial Fibrillation To Be Presented At AHA Scientific Sessions 2016 11/7/2016 10:07:49 AM
Portola (PTLA) Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop Andexxa (Andexanet Alfa) In Germany 11/1/2016 10:49:57 AM
Daiichi Sankyo Release: Anti-HER3 Monoclonal Antibody Patritumab Selected For I-SPY 2 TRIAL In Breast Cancer 10/25/2016 8:43:49 AM
Daiichi Sankyo And Inspirion Delivery Sciences Announce U.S. Licensing Agreement For MorphaBond Formulated With SentryBond Abuse-Deterrent Technology 10/25/2016 7:42:57 AM
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer 10/19/2016 5:47:33 AM